Advertisement

Indikation und Differentialindikation der neuroleptischen Langzeitmedikation

  • H. J. Möller
Conference paper
Part of the Tropon-Symposium book series (BAYERZNS, volume 2)

Zusammenfassung

Unter neuroleptischer Langzeitmedikation wird die langdauernde, mindestens mehrmonatige Applikation von Neuroleptika verstanden. Je nach Zielsetzung dieser langdauernden Applikation von Neuroleptika kann man grundsätzlich unterscheiden zwischen (Heimchen 1979):
  1. a)

    prophylaktischer Langzeitmedikation zur Verhinderung von psychotischen Rezidiven

     
  2. b)

    symptomsuppressiver Langzeitmedikation zur Kupierung chronisch psychotischer Symptomatik.

     

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abbuzzahab FS, Zimmermann RL (1982) Psychopharmacological correlates of postpsychotic depression: A double-blind investigation of haloperidol vs. thiothixene in outpatient schizophrenia. J Clin Psychiatry 43: 105–110Google Scholar
  2. Angst J, Bente D, Berner P, Heimann H, Heimchen H, Hippius H (1971a) Das klinische Wirkungsbild von Clozapin (Untersuchung mit dem AMP-System). Pharmacopsychiat Neuropsychopharmacol 4:201–211Google Scholar
  3. Angst J, Jaenicke H, Padrutt A, Scharfetter C (1971b) Ergebnisse eines Doppelblindversuches von Clozapin im Vergleich zu Laevomepromazin Pharmacopsychiatria 4: 192–200CrossRefGoogle Scholar
  4. Angst J, Woggon B (1975) Klinische Prüfung von fünf Depot-Neuroleptika. Arzneimittelforsch 25: 267–270PubMedGoogle Scholar
  5. APA Task Fotce Report 18. Washington: American Psychiatric Press 1980Google Scholar
  6. Arnold OH, Collard J, Deniker P et al. (1970) Definition and classification of neuroleptics. Mod Probi Pharmacopsychiatry 5: 141–147Google Scholar
  7. Baldessarini RJ, Tarsy D (1978) Tardive dyskinesia. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New YorkGoogle Scholar
  8. Bobon DP (1973) Classifications and terminology of psychotropic drugs. Pharmacopsychiatria 6: 1–12CrossRefGoogle Scholar
  9. Bobon J, Bobon DP, Pinchard A et al. (1972) A new comparative physiognomy of neuroleptics: a collaborative clinical report. Acta Psychiat Belg 72: 542–554Google Scholar
  10. Bobon DP, Gottfries CG (1974) Clinical physiognomy of thioxanthenes. Acta Psychiat Belg 74: 441–568Google Scholar
  11. Borison RL (1985) Pharmacology of antipsychotic drugs. J Clin Psychiatry 46 (4): 25–28PubMedGoogle Scholar
  12. Brannen JO, McEvoy JP, Wilson WH, Petrie WM, Ban TA, Berney SA (1981) A double-blind comparison of bromperidol and haloperidol in newly admitted schizophrenic patients. Phar-macopsychiatria 14: 139–140Google Scholar
  13. Angst J, Bente D, Berner P, Heimann H, Heimchen H, Hippius H (1971a) Das klinische Wirkungsbild von Clozapin (Untersuchung mit dem AMP-System). Pharmacopsychiat Neuropsychopharmacol 4:201–211Google Scholar
  14. Bürki HR, Gaertner HJ, Breyer-Pfaff U, Schied HW (1983) Neuroleptika. Grundlagen und Therapie. In: Langer G, Heimann H (Hrsg) Psychopharmaka. Grundlagen und Therapie. Springer, Wien New YorkGoogle Scholar
  15. Carpenter WT, Stephens JH, Rey AC, Hanlon TE, Heinrichs DW (1982) Early intervention vs. continuous pharmacotherapy of schizophrenia. Psychopharmacol Bull 18: 21–23Google Scholar
  16. Cheung HK (1981) Schizophrenics fully remitted on neuroleptic for 3–5 years — to stop or con-tinue drugs. Br J Psychiatry 138: 490–494PubMedCrossRefGoogle Scholar
  17. Chouinard G, Jones BD (1980) Neuroleptic-induced supersensitivity psychosis: Clinical and pharmacologic characteristics. Am J Psychiatry 137: 16PubMedGoogle Scholar
  18. Cookson J, Silverstone T, Wells B (1981) Double-blind comparative clinical trial of pimozide and chlorpromazine in mania. A test of the dopamine hypothesis. Acta Psychiat Scand 64: 381–397PubMedCrossRefGoogle Scholar
  19. Crawford R, Forest A (1974) Controlled trial of depot fluphenazine in outpatient schizophrenics. Br J Psychiatry 124: 385PubMedCrossRefGoogle Scholar
  20. Crow TJ (1978) The biochemistry of schizophrenia. Br J Hosp Med 5: 532–544Google Scholar
  21. Crow TJ (1981) Positive and negative schizophrenia symptoms and the role of dopamine. Br J Psychiatry 139: 252–254CrossRefGoogle Scholar
  22. Davis JM (1974) Dose equivalence of the antipsychotic drugs. J Psychiat Res 11: 65–69PubMedCrossRefGoogle Scholar
  23. Davis JM (1976) Comparative clinical studies on antipsychotic drugs. In: Sedwall G, Urnes B, Zottermann G (eds) Pharmacodynamics and pharmacokinetics. Pergamon Press, OxfordGoogle Scholar
  24. Davis JM, Garver DL (1978) Neuroleptics: Clinical use in psychiatry. In: Iversen LL, Iversen SD, Snyder SH (eds) Handbook of psychopharmacology, vol 10. Plenum Press, New York LondonGoogle Scholar
  25. Davis JM, Schaffer CB, Killian GA, Kinnard C, Chan C (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull ( Special Report: Schizophrenia )Google Scholar
  26. Deligné P, Bunodière M (1978) Neuroplégiques et neuroleptiques antipsychotiques. I - Définitions et classifications. Ann Anesth Franc X IXGoogle Scholar
  27. Eufe R, Wegener G (1979) Double-blind comparison of 2 depot neuroleptics (perphenazine en-anthate and flupentixol decanoate) in chronic schizophrenia. Nervenarzt 50: 534–539PubMedGoogle Scholar
  28. Falloon I, Watt DC, Shepherd M (1978) A comparative controlled trial of pimozide and fluphen-azine decanoate in the continuation therapy of schizophrenia. Psychol Med 8: 59–70PubMedCrossRefGoogle Scholar
  29. Freyhan FA (1957) Psychomotilität, extrapyramidale Syndrome und Wirkungsweisen neurolep-tischer Therapie (Chlorpromazin, Reserpin, Prochlorperazin). Nervenarzt 28: 504–509PubMedGoogle Scholar
  30. Gaebel W, Pietzcker A (1983) Indikation zur neuroleptischen Langzeitmedikation–Standard-verfahren oder individualprognostisch geleitete Intervention? Nervenarzt 54: 467–476PubMedGoogle Scholar
  31. Gardos G, Cole JO (1973) The importance of dosage in antipsychotic drug administration–A review of dose response studies. Psychopharmacology (Berlin) 29: 221–230CrossRefGoogle Scholar
  32. Gardos G, Cole JO (1976) Maintenance antipsychotic therapy: is the cure worse than the disease? Am J Psychiatry 133: 32–36PubMedGoogle Scholar
  33. Goldberg SC, Schooler NR, Hogarty GE, Roper M (1977) Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy. Arch Gen Psychiatry 34: 171–184PubMedCrossRefGoogle Scholar
  34. Goldstein MS, Rodnick EM, Evans JR, May PRA, Steinberg MP (1978) Drugs and family ther-apy in the after-care of acute schizophrenics. Arch Gen Psychiatry 35: 1169–1177PubMedCrossRefGoogle Scholar
  35. Goodnick PJ, Meltzer HY (1984) Treatment of schizoaffective disorders. Schizophr Bull 10: 30–46PubMedGoogle Scholar
  36. Giudice J del, Clar WG, Gocka EF (1975) Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics 16: 32–36PubMedGoogle Scholar
  37. Haas S, Beckmann H (1982) Pimozide vs. haloperidol in acute schizophrenia. A double-blind controlled study. Pharmacopsychiatria 15: 70–74PubMedCrossRefGoogle Scholar
  38. Heinrich H, Tegeler J (1983) Dyskognitive, apathische und extrapyramidale Syndrome bei Langzeit-Neurolepsie. In: Hippius H, Klein HE (Hrsg) Therapie mit Neuroleptika. Perimed, Erlangen, S 194–202Google Scholar
  39. Helmchen H (1978) Forschungsaufgaben bei psychiatrischer Langzeitmedikation. Nervenarzt 49: 534–538PubMedGoogle Scholar
  40. Heimchen H (1979) Neuroleptische Langzeitmedikation in der Praxis. Mkurse Ärztl Fortbild 29: 800–801Google Scholar
  41. Hertrich O (1965) Differentialindikationen für psychosenspezifische Drogen nach Zielsymptomen. Fortschr Neurol Psychiatr 33: 49–111Google Scholar
  42. Herz MJ, Szymanski H, Simon JC von (1982) Intermittent medication for stable schizophrenic outpatients: An alternative to maintenance medication. Am J Psychiatry 139: 918–922PubMedGoogle Scholar
  43. Hirsch SR, Gaind R, Rohde P, Stevens B, Wing JK (1973) Outpatient maintenance treatment of chronic schizophrenic with fluphenazine decanoate injections: a double-blind placebo trial. Br Med J 41: 118–127Google Scholar
  44. Hogarty GE (1984) Depot-neuroleptics: The relevance of psychosocial factors–A United States perspective. J Clin Psychiatry 45: 36–42PubMedGoogle Scholar
  45. Hogarty GE, Goldberg S, Schooler N, Ulrich R (1974) Drug and sociotherapy in the aftercare of schizophrenic patients. II: Two years relapse rates. Arch Gen Psychiatry 31: 603–618PubMedCrossRefGoogle Scholar
  46. Hogarty GE, Ulrich RF, Mussare F, Aristigueta N (1977) Drug discontinuation among long-term, successfully maintained schizophrenic outpatients. Dis Nerv Syst 37: 494–500Google Scholar
  47. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E (1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients. Arch Gen Psychiatry 36: 1283–1294PubMedCrossRefGoogle Scholar
  48. Hogarty GE, Ulrich RF (1977) Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Arch Gen Psychiatry 34: 297–301PubMedCrossRefGoogle Scholar
  49. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J (1982) Fluphenazine vs. placebo in patients with remitted, ante first-episode schizophrenia. Arch Gen Psychiatry 39: 70–73PubMedCrossRefGoogle Scholar
  50. Kane JM, Rifkin A, Woerner M, Reardon G, Sarantakos S, Schiebel D, Ramos-Lorenzi J (1983) Low dose neuroleptic treatment of outpatient schizophrenica. Arch Gen Psychiatry 40: 893–896PubMedCrossRefGoogle Scholar
  51. Kelder J (1982) Prediction of the Bobon clinical profile of neuroleptics from animal pharmacological data. Psychopharmacology (Berlin) 77: 140–145CrossRefGoogle Scholar
  52. Kissling W, Möller HJ, Walter K, Wittmann B, Krueger R, Trenk D (1985) Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months’ treatment for relapse prevention. Pharmacopsychiatria 18: 240–245CrossRefGoogle Scholar
  53. Klein DF (1968) Importance of psychiatric diagnosis in prediction of clinical drug effect. Psycho-pharmacology (Berlin) 13: 359–386CrossRefGoogle Scholar
  54. Langer G, Sachar EJ, Gruen PH, Halpern F (1977) Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency. Nature 266: 639–645PubMedCrossRefGoogle Scholar
  55. Leff J, Vaughn C (1981) The role of maintenance therapy and relatives expressed emotion in relapse of schizophrenia. A 2-year follow-up. Br J Psychiatry 139: 102–104PubMedCrossRefGoogle Scholar
  56. Leff J, Wing JK (1971) Trials of maintenance therapy in schizophrenia. Br Med J 3: 559–604CrossRefGoogle Scholar
  57. Lehmann HE (1975) Psychopharmacological treatment of schizophrenia. Schizophr Bull 13: 27–45PubMedGoogle Scholar
  58. Lehmann E, Hassel P, Thörner GW, Karrass W (1984) Alternatives Therapiekonzept zur Behandlung psychosomatischer Beschwerden. Fortschr Med 40: 1033–1036Google Scholar
  59. Lehmann E, Quadbeck H, Tegeler J, Farauni M, Heinrich K (1980) Wirkungsdifferenzen bei Hoch-and Standarddosierung von Fluphenazin-Decanoat in Abhängigkeit von Patienten-Merkmalen. Pharmakopsychiat Neuropsychopharmakol 3: 117–129Google Scholar
  60. Lehmann HE, Wilson WH, Deutsch M (1983) Minimal maintenance medication: effect of three dose schedules on relapse rates and symptoms in chronic schizophrenic outpatients. Compr Psychiatry 24: 293–303PubMedCrossRefGoogle Scholar
  61. Marder SR, Putten T van, Mith J, McKenzie J, Lebell H, Faltico G, May PRA (1984) Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 41: 1025–1029PubMedCrossRefGoogle Scholar
  62. Mattes JA, Nayak D (1984) Lithium vs. fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives. Biol Psychiatry 19: 445–449PubMedGoogle Scholar
  63. May PRA, Goldberg SC (1978) Prediction of schizophrenia. Patients’ response to pharmacotherapy. In: Lipton MA (ed) Psychopharmacology — a generation of progress. Raven Press, New YorkGoogle Scholar
  64. Marder SR, Putten T van, Mith J, McKenzie J, Lebell H, Faltico G, May PRA (1984) Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 41: 1025–1029PubMedCrossRefGoogle Scholar
  65. McGonaghy N (1970) Actuarial vs. clinical prediction. Br J Psychiatry 117: 122Google Scholar
  66. Menter RE, Mandel MR (1979) The treatment of psychotic major disorder with drugs and electroconvulsive therapy. J Nerv Ment Dis 12: 726–733Google Scholar
  67. Möller HJ (1986) Methodological problems of long-term studies in psychopharmacology. Pharmacopsychiatria 19: 156–160CrossRefGoogle Scholar
  68. Möller HJ, Kissling W (1986) Advantages and disadvantages of depot-neuroleptics as mainte-nance medication for chronic schizophrenics. Clin Neuropharmacol 9 [Suppl] 41: 259–262Google Scholar
  69. Möller HJ, Zerssen D von (1986) Der Verlauf schizophrener Psychosen unter den gegenwärtigen Behandlungsbedingungen. Springer, Berlin Heidelberg New York TokyoCrossRefGoogle Scholar
  70. Müller P (1983) Was sollen wir Schizophrenen raten? Medikamentöse Langzeitprophylaxe oder Intervallbehandlung? Nervenarzt 54: 477–485PubMedGoogle Scholar
  71. Nelson IC, Bowers MB (1978) Delusional unipolar depression. Description and drug response. Arch Gen Psychiatry 35: 1321–1328PubMedCrossRefGoogle Scholar
  72. Niemegeers CJE (1984) Zur Pharmakologie der Antidepressiva and Neuroleptika. Nervenheilkunde 3: 28–32Google Scholar
  73. Niemeegers CJE, Janssen PAJ (1979) A systematic study of the pharmacological activities of dopamine antagonists. Life Sci 24: 2201–2216CrossRefGoogle Scholar
  74. Overall JE, Hollister LE, Johnson M (1966) Nosology of depression and differential response to drugs. JAMA 195: 946–948PubMedCrossRefGoogle Scholar
  75. Overall JE, Hollister LE, Meyer F (1964) Imipramine and thioridazine in depressed and schizo-phrenic patients: are there specific antidepressant drugs? JAMA 189: 605–608PubMedCrossRefGoogle Scholar
  76. Overall JE, Hollister LE, Shelton J (1969) Broad-spectrum screening of psychotherapeutic drugs: Thiothixene as an antipsychotic and antidepressant. Clin Pharmacol Ther 10: 36–43PubMedGoogle Scholar
  77. Pach J, Wanieck W (1976) Vergleichende Untersuchung zum Tranquilizereffekt von Fluspirilene und Diazepam. Pharmakopsychiatria 9: 61–66CrossRefGoogle Scholar
  78. Paykel JS, Price JS, Gillan RV, Palmai G, Chesser ES (1968) A comparative trial of imipramine and chlorpromazine in depressed patients. Br J Psychiatry 114: 1281–1287PubMedCrossRefGoogle Scholar
  79. Pecknold JC, McClure DJ, Allan T, Wresinski L (1982) Comparison of pimozide and chlorpromazine in acute schizophrenia. Can J Psychiatry 27: 208–212PubMedGoogle Scholar
  80. Pietzcker A, Gaebel W, Köpcke W et al. (1986) A German multicenter study on the neuroleptic long-term therapy of schizophrenic patients. Pharmacopsychiatria 19: 161–166CrossRefGoogle Scholar
  81. Pinto R, Bannerjee A, Ghosh N (1979) A double-blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. Acta Psychiat Scand 60: 313–322PubMedCrossRefGoogle Scholar
  82. Pöldinger W (1975) Kompendium der Psychopharmakotherapie. Privatdruck der Fa. La Roche, 3. Aufl. Basel 1975Google Scholar
  83. Pöldinger W, Sieberns S (1983) Depression-inducing and antidepressive effects of neuroleptics. Experiences with flupenthixol and flupenthixol-decanoate. Neuropsychobiology 10: 131–136PubMedCrossRefGoogle Scholar
  84. Puech A, Lecrubier Y, Simon P (1984) Pharmacological classification of benzamides. Acta Psychiat Scand [Suppl] 311: 139–145CrossRefGoogle Scholar
  85. Raskin A, Schulterbrandt JG, Reating N, Chase C, McKeon JJ (1970) Differential response to chlorpromazine, imipramine, and placebo. A study of subgroups of hospitalized depressed patients. Arch Gen Psychiatry 23: 154–173CrossRefGoogle Scholar
  86. Rifkin A, Quitkin F, Klein DF (1975) Akinesia: A poorly recognized drug induced extrapyramidal disorder. Arch Gen Psychiatry 32: 672–674CrossRefGoogle Scholar
  87. Robertson MM, Trimble MR (1982) Major tranquilizers used as antidepressants. A review. J Affect Disord 4: 173–193PubMedCrossRefGoogle Scholar
  88. Schmidt LG, Schüssler G, Kappes U, Mühlbauer H, Müller-Oerlinghausen B (1982) A double-blind study of the antipsychotic efficacy of perazine compared to haloperidol. Arzneimittelforsch 32: 910–911Google Scholar
  89. Schooler NR, Levine J, Severe JB, Brauzer B, DiMascio A, Klerman GL, Tuason VB (1980) Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. Arch Gen Psychiatry 37: 16–24PubMedCrossRefGoogle Scholar
  90. Schooler NR, Severe J, Levine J et al. (1980) Der Abbruch der neuroleptischen Behandlung bei schizophrenen Patienten und dessen Einfluß auf Rückfälle und auf Symptome der Spätdyskinesie? In: Kryspin-Exner, Hinterhuber H, Schubert H (Hrsg) Ergebnisse der psychiatrischen Therapieforschung. Schattauer, Stuttgart New YorkGoogle Scholar
  91. Seeman P, Tittler M, Tedesco J, Lee T (1977) Neuroleptic sites of membrane action: Non-specific (anesthetic) and specific dopamine receptors. In: Keverling-Buisman JA (ed) Biological activity and chemical structure. Elsevier, Amsterdam Oxford New YorkGoogle Scholar
  92. Sieberns S (1986) Darstellung der Depotneuroleptika. In: Heinrich K, Sieberns S (Hrsg) Das ärztliche Gespräch 40. Internationales Fluanxol-Depot-Kolloquium. pmi Verlag, FrankfurtGoogle Scholar
  93. Simon P, Fermanian J, Ginestedt D (1978) Standard and long acting depot neuroleptics in chronic schizophrenics. Arch Gen Psychiatry 35: 893–897PubMedCrossRefGoogle Scholar
  94. Simon P, Lecrubier Y, Puech AJ (1984) Classification des neuroleptiques. Rev Pract 34 (13): 589–594Google Scholar
  95. Simpson GM, Amin M, Angus JWS, Edwards JG, Hing Go S, Lee JH (1972) Role of antidepressants and neuroleptics in the treatment of depression. Arch Gen Psychiatry 27: 337–345PubMedCrossRefGoogle Scholar
  96. Simpson GM, Watts TPS (1965) Antidepressant drugs. Am J Psychiatry 121: 1028–1029PubMedGoogle Scholar
  97. Spiker DG, Hanin I, Perel JM, Cofsky JE, Rossi AJ, Sorisio D (1982) Pharmacological treatment of delusional depressives. Psychopharmacol Bull 18: 184–186PubMedGoogle Scholar
  98. Spiker DG, Weiss JC, Dealy RC et al. (1985) The pharmacological treatment of delusional depression. Am J Psychiatry 142: 430–436PubMedGoogle Scholar
  99. Stumpf C (1978) Pharmakologie der Psychopharmaka. Dtsch Apothek Ztg 39: 1405–1410Google Scholar
  100. Tansella M, Balestrieri A (1976) The choice of neuroleptics in the treatment of schizophrenia. Arzneimittelforsch 26: 943–945PubMedGoogle Scholar
  101. Task Force on late neurological effects of antipsychotic drugs (1980) Tardive dyskinesia: Summary of a task force report of the American Psychiatric Association. Am J Psychiatry 137: 1163–1172Google Scholar
  102. Tegeler J (1981) Dosierung und Verträglichkeit der Depot-und Langzeitneuroleptika. In: Das ärztliche Gespräch 35. Erfahrungsaustausch über die Anwendung von Depotneuroleptika — unter besonderer Berücksichtigung der Thioxanthen-Depotneuroleptika. Kolloquium der Tropon-Werke 1981Google Scholar
  103. Tegeler J, Floru L (1979) Eine vergleichende Untersuchung der Depot-Neuroleptika Perphenazin Önanthat und Fluspirilen. Pharmakopsychiatria 12: 257–265CrossRefGoogle Scholar
  104. Vaughn CE, Snyder KS, Freeman W (1982) Family factors in schizophrenic relapse: a replication. Schizophr Bull 8: 425–426PubMedGoogle Scholar
  105. Winter K, Fullerton AG, Hussain K, Tarlo L (1973) A comparative double-blind trial of fluspirilene and fluphenazine decanoate in the treatment of chronic schizophrenia. Br J Clin Pract 27: 377–380PubMedGoogle Scholar
  106. Woggon B, Angst J, Margoses N (1975) Gegenwärtiger Stand der neuroleptischen Langzeitbehandlung der Schizophrenie. Nervenarzt 46: 611–616PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • H. J. Möller

There are no affiliations available

Personalised recommendations